MedPath

Expression Analysis of the COPB 2 and Bcl-2 in Early Stages of Endometrial Carcinoma

Completed
Conditions
Endometrial Carcinoma Cellular Diagnosis
Interventions
Procedure: 1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage
Registration Number
NCT05951426
Lead Sponsor
Clinical Center Kragujevac
Brief Summary

COPB2 is a subunit of the intracellular transport system between cell organelles that participates in the regulation of cell division and differentiation. Bcl-2 is a protein that participates in regulating the process of apoptosis. Through the research,investigators tried to examine and establish the correlation of the expression of these two genes in endometrial cancer at an early stage.

Detailed Description

The research was conducted as a prospective controlled clinical experimental study in the period from 2019-2022. in patients who were treated at the Gynecology and Obstetrics Clinic in Clinical Center Kragujevac. Sections of tissue deriving from the exploratory curettage and operative procedure were taken after obtaining informed consent of participants with the declaration of Helsinki and recommendations of the World Health Organization for experiments on human material and after getting approval of the Ethics Committee.

Participants are divided into two groups. Investigators stored the sample (endometrial tissue) in liquid nitrogen under adequate conditions at the Kragujevac Clinical Center, department for Gynecology and Obstetrics and examined the expression of the COPB2 and Bcl-2 gene in endometrial tissue cells of these two groups of patients. In order to examine the relative expression of the gene for the COPB2 subunit and Bcl-2, investigators sampled endometrial tissue from patients with endometrial cancer - experimental group and from patients without cancer - control group. All participants of the experimental group had initial stages of cancer, without the existence of metastases at the time of taking the sample for the study. Gene expression was performed using the Polymerase Chain Reaction method at the Faculty of Science and Mathematics in Kragujevac.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • signed informed consent of the patient
  • pathohistological confirmation of endometrial carcinoma for the experimental group
  • normal endometrial tissue and hyperplasia simplex endometrii for the control group.
Exclusion Criteria
  • malignant disease in the patient whose treatment is still ongoing
  • pathohistological determination of atypical hyperplasia of the endometrial tissue

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
experimental group1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage40 patients in whom Endometrial carcinoma was diagnosed as part of the experimental group.
control group1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage20 patients in whom cancer or atypical hyperplasia of the endometrium was excluded histopathologically.
Primary Outcome Measures
NameTimeMethod
Relative expression COPB2 and BCL-2The laboratory processing of the material lasted 3 months, after all the samples were collected during the clinical part of the research. In the period from 01.03. 2022-01.06.2022.

In order to examine the relative expression of the gene for the COPB2 subunit and Bcl-2, investigators sampled endometrial tissue from patients with endometrial cancer - experimental group and from patients without cancer - control group. All patients of the experimental group had initial stages of cancer, without the existence of metastases at the time of taking the sample for the study. Gene expression was performed using the Polymerase Chain Reaction method

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath